The new approval strengthens the suite of over 60 approved patents and patent applications owned and licensed by the company. It cover all aspects of the company’s technology for producing autologous Biopumps, that are capable of producing a wide range of therapeutic proteins when implanted into humans.
Andrew Pearlman, CEO of Medgenics, said: “The granting of additional patents is always very important to a technology driven company such as Medgenics. We now have issued or applied for patents in all major jurisdictions covering key aspects of our platform technology for obtaining micro-organs from a patient’s tissue, processing them to produce therapeutic proteins and then reinserting them into the patient to provide continuous delivery of therapeutic proteins over an extended period of time.”